References

Endometriosis: epidemiology, diagnosis and clinical management

10.1007/s13669-017-0187-1 · 2017 · External reference

Endometriosis: epidemiology, and etiological factors

10.1002/9781444398519.ch2 · 2011 · External reference

Endometriosis diagnosis and medical treatment: present and future

10.47307/gmc.2021.129.2.12 · 2021 · External reference

Brief update on endometriosis treatment

10.1016/j.mefs.2011.01.002 · 2011 · External reference

Recurrence of endometriosis and its control

10.1093/humupd/dmp007 · 2009 · External reference

ESHRE guideline: endometriosis

10.1093/hropen/hoac009 · 2022 · External reference

Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis–a pilot study

10.1016/j.contraception.2008.07.017 · 2009 · External reference

The effects of implanon in the symptomatic treatment of endometriosis

2005 · External reference

Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon)

10.1783/0000000052972799 · 2005 · External reference

Effect of Mirena intrauterine device combined with GNRH-A on endometriosis, sex hormone level and carbohydrate antigen 125

10.14715/cmb/2022.68.7.4 · 2022 · External reference

Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial

10.1111/j.1479-828x.2010.01152.x · 2010 · External reference

Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial

10.1016/j.fertnstert.2018.07.003 · 2018 · External reference

Experimental development of the graphic rating method

1921 · External reference

Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety

10.1186/s12905-022-02122-0 · 2022 · External reference

Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis

10.1111/j.1479-828x.2007.00727.x · 2007 · External reference

Estrogen receptor-β, estrogen receptor-α, and progesterone resistance in endometriosis

10.1055/s-0029-1242991 · 2010 · External reference

Progesterone resistance in endometriosis: link to failure to metabolize estradiol

10.1016/j.mce.2005.11.041 · 2006 · External reference

Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars

10.1016/j.xfss.2024.10.004 · 2025 · External reference

Progesterone receptor status predicts response to progestin therapy in endometriosis

10.1210/jc.2018-01227 · 2018 · External reference

Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study

10.1080/09513590.2020.1807502 · 2021 · External reference

Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study

10.1016/j.fertnstert.2003.09.029 · 2004 · External reference

Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis

10.1080/02656736.2019.1595179 · 2019 · External reference

The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis

10.1186/s12958-025-01349-4 · 2025 · External reference

ESHRE guideline: management of women with endometriosis

10.1093/humrep/det457 · 2014 · External reference

Surgical management of endometriosis

10.1016/j.bpobgyn.2004.03.004 · 2004 · External reference

Extended GnRH Agonist and NETA Add-Back: an effective and safe option for refractory endometriosis/adenomyosis pain

10.13005/bpj/3226 · 2025 · External reference